| Autor: |
Dell’Osso, Bernardo, Cremaschi, Laura, Palazzo, Maria Carlotta, Spagnolin, Gregorio, Cattaneo, Alma, Grancini, Benedetta, Maggi, Matteo, Altamura, Alfredo Carlo |
| Zdroj: |
Expert Opinion on Drug Safety; September 2014, Vol. 13 Issue: 9 p1199-1208, 10p |
| Abstrakt: |
Introduction:Several randomized controlled trials (RCTs), conducted in schizophrenic and bipolar patients, have documented the efficacy and tolerability of asenapine as monotherapy both for short- and long-term treatment. However, evidence on its augmentative use is more limited and related to the manic/mixed phase of bipolar disorder (BD).Areas covered:The present article reviews augmentative asenapine efficacy and safety/tolerability in the treatment of BD. It also includes some original cases of bipolar patients treated with add-on asenapine in the short- and long-term.Expert opinion:To date, only a single RCT with manic/mixed patients with partial response to mood-stabilizer monotherapy supports the efficacy and safety/tolerability of augmentative asenapine to lithium/valproate, both in acute and long-term treatment. Additionally, two case reports confirm the overall effectiveness of augmentative asenapine to clozapine and valproate. Our case series, consisting of 4 bipolar patients treated with adjunctive asenapine to mood stabilizers and atypical antipsychotics – with treatment duration ranging from 1 to 14 months – provided clinical results that are consistent with literature data. Taken as a whole, available evidence seems to support the efficacy and safety of adjunctive asenapine in bipolar patients, though additional studies with active comparators are requested to confirm the current body of evidence. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
